For physicians

Oasmia has developed a new excipient platform providing improved opportunities within the field of cancer treatment. An important feature is the improvement of the well-known substance paclitaxel which chemically belongs to the taxane group. The lipophilic structure of paclitaxel makes it extremely difficult to dissolve in water.

Paclitaxel is used all over the world in the treatment of different types of cancer and is the active product ingredience (API) in for example Taxol^®.

Paclitaxel has been a main treatment option for ovarian, breast and non-small cellular lung (NSCL) cancer. In advanced ovarian and NSCL cancer paclitaxel in adjuvant therapy with platinum derivative has been the first-line treatment choice. In the attending of breast cancer both paclitaxel and docetaxel have successfully been used both as first and second line options even in patients showing anthracycline resistance. 

A Paclical^® micelle

   

Benefits of Paclical^®

- no premedication
- short infusion time
- rapid distribution of the drug to the tumour
- nanoparticles
- water soluble

Existing methods of treatment - a comparison
The commonly used drug, Taxol^® with paclitaxel as API, also contains additives of ethanol and Cremophor EL (polyoxyethylated castor oil) which are associated with adverse side effects. Prior to being treated with Taxol^® the patient must be premedicated with steroids and histamine blockers to avoid hypersensitive reactions. Administration of high doses of steroids can cause problems for the patient such as hyperglycaemia. Cremophor EL is also considered as being the cause of the non-linear pharmacokinetic profile of Taxol^®.